Nikita Mehra, medical oncologist in India, and Guilherme Perini, hematologist in Brazil, join the show to give a first-hand perspective on what it’s like to practice oncology in low and middle income countries. They begin by explaining variation in income levels and cancer care access within their own cities, expound on screening programs and ability to travel for care among their populations, share the testing and diagnostics procedures and availability, describe the market and supply of treatments in India and Brazil vs the US, comment on how their country’s regulatory bodies approve and set the course for reimbursement of new therapies, and a whole lot more.
N/A
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
